Effusion Cytology
A High-Fidelity Patient-Derived Organoid Platform Recapitulates the Dynamic Metabolic Landscape of Cisplatin Tolerance in Mesothelioma
Cancers 2026 May 7 [Link] Zivile Useckaite, Ashleigh J Hocking, Lauren A Mortimer, John Salamon, Simon Lee, Yazad Irani, Lucy Franzon, Arya L Arul, Sarita Prabhakaran, Sonja Klebe Abstract Background: Pleural mesothelioma (PM) is characterised by often rapid therapeutic failure and chemotherapy resistance. While terminal resistance is well studied, the initial transition into a drug-tolerant…
Read MoreDiagnostic Yield of Malignant Pleural Effusion in Various Primary and Metastatic Cancers: Insights Across Cancer Subtypes
Pulmonary Medicine 2026 [Link] Santosh Basyal, Antony D Rawindraraj, Rahul Parajuli, Shardul Bhattarai, Laxman Wagle, Kritick Bhandari, Vikas Pathak Abstract Objective/background: Pleural fluid cytology remains a cornerstone in diagnosing malignant pleural effusions (MPEs); however, its diagnostic yield varies considerably across cancer subtypes. This study is aimed at evaluating the diagnostic performance of cytology stratified by…
Read MoreBAP-1 in the diagnosis of malignant pleural mesothelioma
Respiratory Medicine and Research 2025 November 28 [Link] Irene Sansano, Ana Vázquez, Oscar Persiva, Marc Simó, Leire Sánchez, Pilar Montoya, Carme Dinarès, Carmen Alemán Abstract Background: The diagnosis of malignant pleural mesothelioma (MPM) can be challenging for clinicians and pathologists. Patients and methods: This study included all patients diagnosed with pleural mesothelioma between October 2013…
Read MoreArtificial Intelligence in Pleural Diseases: Current Applications and Next Steps
Thoracic Research and Practice 2026 January 30 [Link] Ferhan Karataş, Öner Dikensoy Abstract Pleural diseases pose a significant burden on healthcare systems due to diagnostic challenges and high costs. Artificial intelligence (AI) has the potential to provide faster, more accurate, and more reliable results in the diagnosis of these diseases. This review evaluates the current…
Read MorePotential utility of miRNAs derived from pleural fluid extracellular vesicles to differentiate between benign and malignant pleural effusions
Translational Lung Cancer Research 2025 January 24 [Link] Tian Mun Chee, Caeli J Zahra, Kwun M Fong, Ian A Yang, Rayleen V Bowman Abstract Background: Cytological examination is of suboptimal sensitivity but high specificity for the diagnosis of malignant pleural effusions (MPEs). Pleural fluid extracellular vesicles (PFEVs) are enriched with disease-specific microRNAs (miRNAs) which may…
Read MoreRole of Immunocytochemistry in the Cytological Diagnosis of Mesothelioma
Acta Cytologica 2024 December 12 [Link] Claire W Michael, Shannon Alexandra Rodgers Abstract Background: Mesothelioma is an aggressive malignancy of the serosal surfaces with very poor prognosis. It traditionally manifests in older patients and at an advanced stage which results in minimal improvement in prognosis despite the recent advances in management. Early detection would therefore…
Read MoreApplication of the international system for reporting serous fluid cytopathology on pleural effusion cytology with paired pleural biopsy: A new insight and novel approach on risk of malignancy
Cytopathology 2024 August 1 [Link] Zahra Maleki, Ashleigh J Graham, Robert Jones, Ricardo Pastorello, Paul Morris, Alessandra C Schmitt, Erika F Rodriguez Abstract Introduction: The risk of malignancy (ROM) remains an area of interest for further evaluation in reporting systems including in International System for reporting serous fluid cytopathology (TIS), which is a standardized system…
Read MoreCharacterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma
Scientific Reports 2024 July 10 [Link] Riki Okita, Tomoya Senoo, Yuka Mimura-Kimura, Yusuke Mimura, Tomoyuki Murakami, Eiji Ikeda, Masanori Okada, Hidetoshi Inokawa, Keisuke Aoe Abstract The clinical impact of soluble molecules in pleural effusion (PE) is unclear in patients with malignant pleural mesothelioma (MPM). In this single-center, retrospective, observational study, we assessed soluble forms of…
Read MoreInvestigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma
Diagnostic Cytopathology 2024 January 20 [Link] Nazli Sena Şeker, Emel Tekin, Güntülü Ak, Muzaffer Metintaş, Selma Metintaş, Emine Dündar Abstract Background: Mesothelioma is a malignant neoplasm with a poor survival rate. We aimed to investigate the importance of BAP1, MTAP (IHC), and p16/CDKN2A homozygous deletion (FISH) in cytologic material obtained from pleural effusion sampling, which…
Read MorePleural Mesothelioma: Advances in Blood and Pleural Biomarkers
Journal of Clinical Medicine 2023 November 9 [Link] Claudio Sorino, Michele Mondoni, Giampietro Marchetti, Sergio Agati, Riccardo Inchingolo, Federico Mei, Sara Flamini, Filippo Lococo, David Feller-Kopman Abstract Pleural mesothelioma (PM) is a type of cancer that is highly related to exposure to asbestos fibers. It shows aggressive behavior, and the current therapeutic approaches are usually…
Read More
Skip to content